Answers are grounded in this paper and cite their sources.
Ductal carcinoma in situ (DCIS) is a heterogeneous non-invasive breast neoplasm with variable biological and immune-related features. Human epidermal growth factor receptor 2-positive (HER2 +) DCIS is enriched in immune infiltration and aggressive pathological characteristics; however, its molecular heterogeneity remains poorly characterized. HER2DX is a clinically validated genomic assay developed for early-stage HER2+ invasive breast cancer that integrates immune, proliferation, luminal, and HER2-related gene expression signatures. Improved biological characterization of HER2+ DCIS may help identify molecular heterogeneity relevant to future biomarker development and risk-stratification strategies. We retrospectively selected 67 cases of pure HER2 3+ DCIS (pTisN0) diagnosed between 2010 and 2025 based on the availability of adequate archival tissue. All cases underwent centralized pathological review, including confirmation of HER2 status, followed by HER2DX analysis. Clinicopathological variables, stromal tumor-infiltrating lymphocytes (TILs), tumor immune microenvironment (TIME) patterns, and tertiary lymphoid structures (TLS) were centrally evaluated. HER2DX testing was performed on formalin-fixed paraffin-embedded samples. Associations between HER2DX signatures and clinicopathological features were analyzed using correlation and comparative statistical analyses. HER2DX profiles were compared with 496 HER2+ pT1N0 invasive breast cancer cases from established clinical cohorts. HER2DX analysis was successfully performed in all 67 HER2+ DCIS samples and revealed substantial transcriptomic heterogeneity despite homogeneous HER2 3+ expression by immunohistochemistry. The HER2DX immune (IGG) signature strongly correlated with stromal TIL levels, immune-inflamed TIME patterns, and TLS presence, suggesting that HER2DX signatures are associated with biologically relevant features of the immune microenvironment in HER2+ DCIS. The luminal signature was significantly associated with hormone receptor status, while the proliferation signature correlated with Ki-67 expression despite an overall low proliferative profile. Although all DCIS were HER2 3+, 24% and 6% of cases were classified as ERBB2 -medium and ERBB2 -low, respectively. Comparative analyses showed that HER2+ DCIS shares key immune and HER2-related transcriptomic features with stage 1 HER2+ invasive breast cancer, with the main differences observed in proliferation-related biology. HER2DX profiling reveals that HER2+ DCIS comprises biologically distinct tumors with variable immune, luminal, proliferative, and HER2-related transcriptomic features despite homogeneous HER2 protein overexpression. HER2DX signatures showed biologically coherent associations with the immune microenvironment and identified molecular similarities between HER2+ DCIS and stage 1 HER2+ invasive breast cancer. These findings support the use of transcriptomic approaches to improve the biological characterization of HER2+ DCIS.
No takes yet. Share an insight, caveat, or question.
Sanfeliu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: